Valuation: Luxempart SA

Market Cap 1.5B 1.75B 1.41B 1.28B 2.43B 168B 2.45B 16.63B 6.46B 84.15B 6.58B 6.43B 279B P/E 2024 *
-
P/E 2025 -
Enterprise Value 1.5B 1.75B 1.41B 1.28B 2.43B 168B 2.45B 16.63B 6.46B 84.15B 6.58B 6.43B 279B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
40.89%
Yield 2024
3.3%
Yield 2025 4.06%
Manager TitleAgeSince
Chief Executive Officer 54 27/04/2020
Director of Finance/CFO - 01/04/2022
Chief Operating Officer - 01/01/2024
Director TitleAgeSince
Chairman 66 24/04/2023
Director/Board Member 70 27/04/2015
Director/Board Member 54 01/05/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.18%-0.20%-15.75%+44.07% 115B
-1.07%-5.87%-24.30%+78.21% 97.38B
-0.88%-2.78%-22.68%+40.54% 32.13B
-0.05%-1.93%+41.72%+78.05% 22.16B
-0.47%-0.28%-24.06%+63.96% 17.59B
+0.90%+2.24%+36.35%+33.21% 17.43B
+2.22%+0.29% - - 16.02B
+0.65%+0.91%-10.17%+4.54% 14.3B
-1.48%-3.17% - - 11.7B
Average 0.00%-1.22%-2.70%+48.94% 38.16B
Weighted average by Cap. -0.23%-1.87%-12.39%+55.35%

Financials

2024 2025
Net sales 50.29M 58.66M 47.06M 43.02M 81.22M 5.62B 82.03M 557M 216M 2.82B 220M 215M 9.33B 278M 325M 260M 238M 449M 31.08B 454M 3.08B 1.2B 15.6B 1.22B 1.19B 51.64B
Net income 30.48M 35.55M 28.52M 26.07M 49.22M 3.4B 49.71M 337M 131M 1.71B 133M 131M 5.65B 261M 304M 244M 223M 421M 29.14B 426M 2.89B 1.12B 14.62B 1.14B 1.12B 48.41B
Net Debt - -
Logo Luxempart SA
Luxempart SA is a Luxembourg-based investment company which invests in listed and private equity, as well as in private equity funds. The Company is active in Luxembourg, Belgium, France, Italy and Germany, where it manages a portfolio of listed and unlisted companies. Through Luxempart Capital Partners and Indufin Capital Partners (ICP), Luxempart also runs private equity activities. ICP is a joint-venture with the Belgian family holding Eik NV. The Company holds stakes in a number of private companies, including SES, RTL Group, Atenor, Foyer Finance, Foyer SA, SEO, PNE Wind, Pescanova, Mirato, Indufin Capital Partners - ICP Sicar, IEE, Quip, DS Care, Ekkio Capital, Thrombogenics, IP Sante domicile, Octopede Fonds private equity, among others. It also holds a majority stake in Euphaco (ABC Chemical).
Employees
-